FDA approves 1st new drug to treat schizophrenia in more than 30 years
This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a new alternative to the antipsychotic medications peo
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March of 2024. Royalty Pharma had acquired an interest in PureTech's royalty in KarXT.
Cranswick flags strong annual results, PureTech schizophrenia treatment gets US approval
London open The FTSE 100 is expected to open eight points higher on Friday, having closed up 0.2% on Thursday at 8,284.91.
PureTech Health celebrates KarXT approval by FDA for schizophrenia
PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone triggers payments to it totalling USD29 million under agreements with Royalty Pharma and Karuna Therapeutics,
Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment
Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
First Novel Schizophrenia Treatment in Decades Gains FDA Approval
The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration approved the drug on Thursday, greenlighting the first of a new class of treatments that could help stabilize patients’ symptoms without the uncomfortable side effects that accompany existing antipsychotics.
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...
Security20h
PureTech Systems awarded contract to help secure critical international waterway
PureActiv will deploy across multiple locations to detect unauthorized access as ships travel through the waterway system.
London midday: FTSE gains as China stocks enjoy best week since 2008
London stocks had extended gains by midday on Friday as Chinese markets enjoyed their best week since 2008 on the back of ...
Exchange 4 Media7h
Agility and AI: How digital marketing agencies are redefining brand building
Industry leaders came together at the e4m IDAC Summit 2024 to discuss the shifts in the marketing landscape and the ...
Security16h
PureTech Systems adds Access Control Auto-Verify to eliminate nuisance alarms
The PureActiv enhancement automatically validates access control security violations and dismisses nuisance alarms.
French inflation ‘crash’ raises pressure for interest rate cuts
Christine Lagarde is under pressure to ramp up the pace of interest rate cuts in the eurozone after French and Spanish ...
Puretech Expands Integrated Solutions With Axis Communications
PureTech Systems, a leader in geospatial AI-boosted video analytics for perimeter and border security, is excited to announce ...
Yahoo Finance8h
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Cobenfy was invented at PureTech Health Plc (NASDAQ:PRTC). FDA approval triggers two separate milestone payments to PureTech totaling $29 million. Price Action: BMY stock is up 6.34% at $53.30 ...